EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 908 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom... June 18, 2026 Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... October 25, 2019 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Load more HOT NEWS FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment...
